1
2
3
4
5
6
1. Neefjes J, Jongsma ML, Paul P, Bakke O. Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nat Rev Immunol. 2011; 11:823-836. 2. Jones EY, Fugger L, Strominger JL, Siebold C. MHC class II proteins and disease: a structural perspective. Nat Rev Immunol. 2006; 6:271-282. 3. Jixin Zhong, Jun-Fa Xu, Ping Yang, Yi Liang and Cong-Yi Wang. Innate Immunity in the Recognition of -Cell Antigens in Type 1 Diabetes. InTech. 2011. ISBN: 978-953-307-362-0. 4. Guardiola J, Maffei A. Control of MHC class II gene expression in autoimmune, infectious, and neoplastic diseases. Crit Rev Immunol. 1993; 13:247-268. 5. Lahiru Handunnetthi, MSc, Sreeram V. Ramagopalan, DPhil, George C. Ebers, MD and Julian C. Knight, DPhil. Regulation of MHC class II gene expression, genetic variation and disease. Genes Immun. 2010; 11:99?112. 6. Jabrane-Ferrat N, Nekrep N, Tosi G, Esserman L, Peterlin BM. MHC class II enhanceosome: how is the class II transactivator recruited to DNA?bound activators? Int Immunol. 2003; 15:467-475. 7
7. Seguin-Esteves Q, De Palma R, Krawczyk M, Leimgruber E, Villard J, Picard C, Tagliamacco A, Abbate G, Gorski J, Nocera A, Reith W. The Transcription Factor RFX Protects MHC Class II Genes against Epigenetic Silencing by DNA Methylation. J Immunol. 2009; 183:2545-2553. 8. Wright KL, Ting JP. In vivo footprint analysis of the HLA-DRA gene promoter: cell-specific interaction at the octamer site and up-regulation of X box binding by interferon gamma. Proc Natl Acad Sci U S A. 1992; 89:7601-7605. 9. Ina Y, Koide Y, Nezu N, Yoshida TO. Regulation of HLA class II antigen expression: intracellular signaling molecules responsible for the regulation by IFN-gamma and cross-linking of Fc receptors in HL-60 cells. J Immunol. 1987; 139:1711-1717. 10. Koide Y, Ina Y, Nezu N, Yoshida TO. Calcium influx and the Ca2+-calmodulin complex are involved in interferon-gamma-induced expression of HLA class II molecules on HL-60 cells. Proc Natl Acad Sci U S A. 1988; 85:3120-3124. 11. Gokturk B, Artac H, van Eggermond MJ, van den Elsen P, Reisli. Type III bare lymphocyte syndrome associated with a novel RFXAP mutation: a case report. Int J Immunogenet. 2012; 39:362-364. 12. Ouederni M, Vincent QB, Frange P, Touzot F, Scerra S, Bejaoui M, Bousfiha A, Levy Y, Lisowska- Grospierre B, Canioni D, Bruneau J, Debr? M, Blanche S, Abel L, Casanova JL, Fischer A, Picard C. Major histocompatibility complex class II expression deficiency caused by a RFXANK founder mutation: a survey of 35 patients. Blood. 2011; 118:5108-5118. 13. Dziembowska M, Fondaneche MC, Vedrenne J, Barbieri G, Wiszniewski W, Picard C, Cant AJ, Steimle V, Charron D, Alca-Loridan C, Fischer A, Lisowska-Grospierre B. Three novel mutations of the CIITA gene in MHC class II-deficient patients with a severe immunodeficiency. Immunogenetics. 2002; 53:821-829. 14. Wiszniewski W, Fondaneche MC, Le Deist F, Kanariou M, Selz F, Brousse N, Steimle V, Barbieri G, Alcaide-Loridan C, Charron D, Fischer A, Lisowska- Grospierre B. Mutation in the class II trans-activator leading to a mild immunodeficiency. J Immunol. 2001; 167:1787-1794. 15. Hegde NR, Chevalier MS, Johnson DC. Viral inhibition of MHC class II antigen presentation. Trends Immunol. 2003; 24:278-285. 16. Gregersen PK, Behrens TW. Genetics of autoimmune diseases-disorders of immune homeostasis. Nat Rev Genet. 2006; 7:917-928. 17. Giordano C, Amato MC, Ciresi A, Citarrella R, Mantione L, Accidenti M, Panto F, Guarnotta V, Allotta ML, Criscimanna A, Galluzzo A. Predictors of microvascular complications in type 1 diabetic patients at onset: the role of metabolic memory. Eur J Intern Med. 2011; 22:266-274. 18. Culina S, Brezar V, Mallone R. Insulin and type 1 diabetes: immune connections. Eur J Endocrinol. 2012; Epub ahead of print. 19. Pimentel TA, Sampaio AL, D'Acquisto F, Perretti M, Oliani SM. An essential role for mast cells as modulators of neutrophils influx in collagen-induced arthritis in the mouse. Lab Invest. 2011; 91:33-42. 20. Rosloniec EF, Brand DD, Myers LK, Esaki Y, Whittington KB, Zaller DM, Woods A, Stuart JM, Kang AH. Induction of autoimmune arthritis in HLA- DR4 (DRB1*0401) transgenic mice by immunization with human and bovine type II collagen. J Immunol. 1998; 160:2573-2578. 21. Rosloniec EF, Brand DD, Myers LK, Whittington KB, Gumanovskaya M, Zaller DM, Woods A, Altmann 8
DM, Stuart JM, Kang AH. An HLA-DR1 transgene confers susceptibility to collagen-induced arthritis elicited with human type II collagen. J Exp Med. 1997; 185:1113-1122. 22. Rosloniec EF, Whittington KB, Zaller DM, Kang AH. HLA-DR1 (DRB1*0101) and DR4 (DRB1*0401) use the same anchor residues for binding an immunodominant peptide derived from human type II collagen. J Immunol. 2002; 168:253-259. 23. Xu M, Li J, Gulfo JV, Von Hofe E, Humphreys RE. MHC Class II Allosteric Site Drugs: New Immunotherapeutics for Malignant, Infectious and Autoimmune Diseases. Scand J Immunol. 2001; 54:39-44. 24. Krief P, Boucheix C, Billard C, Mishal Z, Van Agthoven A, Fiers W, Azzarone B. Modulation of expression of class II histocompatibility antigens by secretion of a cellular inhibitor in K562 leukemic cells. Eur J Immunol. 1987; 17:1021-1025. 25. Park HL, Kim YJ, Na HN, Park MY, Kim JY, Yun CW, Nam JH. IK induced by Coxsackievirus B3 infection transiently down-regulates expression of MHC class II through increasing camp. Viral Immunol. In printing 26. Vedrenne J, Assier E, Pereno R, Bouzinba-Segard H, Azzarone B, Jasmin C, Charron D, Krief P. Inhibitor (IK) of IFN-gamma induced HLA class II antigens expression also inhibits HLA class II constitutive expression in the human Raji B cell line. Oncogene. 1997; 14:1453-1461. 27. Muraoka M, Hasegawa H, Kohno M, Inoue A, Miyazaki T, Terada M, Nose M, Yasukawa M. IK cytokine ameliorates the progression of lupus nephritis in MRL/lpr mice. Arthritis Rheum. 2006; 54:3591-3600. 28. Cao LX, Le Bousse-Kerdiles MC, Clay D, Oshevski S, Jasmin C, Krief P. Implication of a new molecule IK in CD34+ hematopoietic progenitor cell proliferation and differentiation. Blood. 1997; 89:3615-3623. 29. Shao R, Liu X, Ding Y, Chen X, Gao R, He J, Wang Y. Characterization of IK cytokine expression in mouse endometrium during early pregnancy and its significance on implantation. Int J Mol Med. 2012; 30:615-621. 30. Kang H, Wu WY, Lo BK, Yu M, Leung G, Shapiro J, McElwee KJ. Hair follicles from alopecia areata patients exhibit alterations in immune privilege-associated gene expression in advance of hair loss. J Invest Dermatol. 2010; 130:2677-2680. 31. Huber S. Host immune responses to coxsackievirus B3. Curr Top Microbiol Immunol 2008; 323:199?221. 32. Leipner C, Borchers M, Merkle I, Stelzner A. Coxsackievirus B3-induced myocarditis in MHC class II-deficient mice. J Hum Virol 1999; 2:102?114. 33. Seko Y, Tsuchimochi H, Nakamura T, Okumura K, Naito S, Imataka K, Fujii J, Takaku F, Yazaki Y. Expression of major histocompatibility complex class I antigen in murine ventricular myocytes infected with Coxsackievirus B3. Circ Res 1990; 67:360?367. 34. De Wall SL, Painter C, Stone JD, Bandaranayake R, Wiley DC, Mitchison TJ, Stern LJ, DeDecker BS. Noble metals strip peptides from class II MHC proteins. Nat Chem Biol. 2006; 2:197-201. 35. Kallinteris NL, Powell D, Blackwell CE, Kim M, Lu X, Wu S, Humphreys RE, Xu M, von Hofe E. Ii- Key/MHC class II epitope peptides as helper T cell vaccines for cancer and infectious disease. Front Biosci. 2006; 11:46-58. 36. Perez SA, Kallinteris NL, Bisias S, Tzonis PK, Georgakopoulou K, Varla-Leftherioti M, Papamichail M, Thanos A, von Hofe E, Baxevanis CN. Results from a phase I clinical study of the novel Ii-Key/HER- 2/neu(776-790) hybrid peptide vaccine in patients with 9
prostate cancer. Clin Cancer Res. 2010; 16:3495-3506. 37. Holmes JP, Benavides LC, Gates JD, Carmichael MG, Hueman MT, Mittendorf EA, Murray JL, Amin A, Craig D, von Hofe E, Ponniah S, Peoples GE. Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine. J Clin Oncol. 2008; 26:3426-3433. 38. Kallinteris NL, Lu X, Blackwell CE, von Hofe E, Humphreys RE, Xu M. Ii-Key/MHC class II epitope hybrids: a strategy that enhances MHC class II epitope loading to create more potent peptide vaccines. Expert Opin Biol Ther. 2006; 6:1311-1321. 10